Treatment with this construct, Ad-522E-TK, in combination with the prodrug ganciclovir (GCV) was found for the first time to kill both androgen-independent prostate cancer and bone stromal cell lines in vitro and to inhibit the prostate tumor growth in an xenograft model. Here, TKT is linked to prostate neoplasm.